Skip to main content Skip to navigation
BUV496 Mouse Anti-Rat CD161a
Product Details
Down Arrow Up Arrow


BD OptiBuild™
CD161/Cd161; CD161a, Klrb1a, Nkrp1a/NKR-P1A; CD161b, Klrb1b, Nkrp1b/NKR-P1B
Mouse (Tested in Development)
Mouse IgG1, κ
Not reported
Flow cytometry (Qualified)
0.2 mg/ml
AB_2874504
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BUV496 under optimal conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions.  More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).

Product Notices

  1. This antibody was developed for use in flow cytometry.
  2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  3. Researchers should determine the optimal concentration of this reagent for their individual applications.
  4. An isotype control should be used at the same concentration as the antibody of interest.
  5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
  9. BD Horizon Brilliant Ultraviolet 496 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,575,303; 8,354,239.
750314 Rev. 4
Antibody Details
Down Arrow Up Arrow
10/78

The 10/78 monoclonal antibody recognizes the rat CD161 proteins, CD161a (also known as, Klrb1a, or Nkrp1a/NKR-P1A), and CD161b (Klrb1b, Nkrp1b/NKR-P1B). These type II transmembrane glycoproteins have an extracellular C-type lectin domain and thus belong to the C-type lectin superfamily. These CD161 proteins form ~ 60 kDa homodimers that are expressed on natural killer cells and subsets of T lymphocytes, activated monocytes, and dendritic cells. The 10/78 antibody competes with the previously-described 3.2.3 antibody for binding to these CD161 proteins. CD161 molecules are C-type lectin-like receptors that can either activate (CD161a) or inhibit (CD161b) effector leucocyte responses, eg, cytotoxicity or cytokine production, against target cells which express C-type lectin-like related (Clr) molecules. Although several members of the Klrb1 gene family have been identified in the mouse and rat, only a single human KLRB1 homolog has been discovered.

The antibody was conjugated to BD Horizon™ BUV496 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye is a tandem fluorochrome of BD Horizon BUV395 with an Ex Max of 348-nm and an acceptor dye with an Em Max at 496-nm. BD Horizon BUV496 can be excited by the ultraviolet laser (355 nm) and detected with a 515/30 nm filter with a 450LP. Due to the excitation of the acceptor dye by other laser lines, there may be significant spillover into the channel detecting BD Horizon V500 or BV510 (eg, 525/40-nm filter). However, the spillover can be corrected through compensation as with any other dye combination.

750314 Rev. 4
Format Details
Down Arrow Up Arrow
BUV496
The BD Horizon Brilliant™ Ultraviolet 496 (BUV496) Dye is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This tandem fluorochrome is comprised of a BUV395 donor with an excitation maximum (Ex Max) of 350-nm and an acceptor dye with an emission maximum (Em Max) at 496-nm. BUV496, driven by BD innovation, is designed to be excited by the ultraviolet laser (355-nm) and detected using an optical filter centered near 500-nm (e.g., 515/30-nm bandpass filter). The acceptor dye can be excited by the Violet (405-nm) laser resulting in cross-laser excitation and fluorescence spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
BUV496
Ultraviolet 355 nm
350 nm
496 nm
750314 Rev.4
Citations & References
Down Arrow Up Arrow

Development References (14)

  1. Bezouska K, Vlahas G, Horvath O, et al. Rat natural killer cell antigen, NKR-P1, related to C-type animal lectins is a carbohydrate-binding protein. J Biol Chem. 1994; 269(24):16945-16952. (Biology). View Reference
  2. Bezouska K, Yuen CT, O'Brien J, et al. Oligosaccharide ligands for NKR-P1 protein activate NK cells and cytotoxicity. Nature. 1994; 372(6502):150-157. (Biology). View Reference
  3. Chambers, W.H., Vujanovic, N.L, et al. Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J Exp Med. 1989; 169:1373-1389. (Biology). View Reference
  4. Fujimura T, Yang XF, Soriano R, Ogawa T, Kobayashi M, Jiang H. Cellular surface molecular and cytokine gene expression in rat heart allografts under optimal doses of cyclosporine and FK 506. Transplant Proc. 1998; 30(4):1023-1026. (Clone-specific: Immunohistochemistry). View Reference
  5. Josien R, Heslan M, Soulillou JP, Cuturi MC. Rat spleen dendritic cells express natural killer cell receptor protein 1 (NKR-P1) and have cytotoxic activity to select targets via a Ca2+-dependent mechanism. J Exp Med. 1997; 186(3):467-472. (Biology). View Reference
  6. Kirkham CL, Carlyle JR. Complexity and Diversity of the NKR-P1:Clr (Klrb1:Clec2) Recognition Systems. Front Biosci. 2014; 5(5):1-16. (Clone-specific). View Reference
  7. Kraus E, Lambracht D, Wonigeit K, Hunig T. Negative regulation of rat natural killer cell activity by major histocompatibility complex class I recognition. Eur J Immunol. 1996; 26(11):2582-2586. (Clone-specific: Flow cytometry, Immunoprecipitation). View Reference
  8. Lanier LL. Natural killer cells: from no receptors to too many. Immunity. 1997; 6(4):371-378. (Biology). View Reference
  9. Li J, Rabinovich BA, Hurren R, Shannon J, Miller RG. Expression cloning and function of the rat NK activating and inhibitory receptors NKR-P1A and -P1B. Int Immunol. 2003; 15(3):411-416. (Clone-specific: Activation, Calcium Flux, Cytotoxicity, Flow cytometry, Functional assay, Inhibition). View Reference
  10. Ryan JC, Niemi EC, Nakamura MC, Seaman WE. NKR-P1A is a target-specific receptor that activates natural killer cell cytotoxicity. J Exp Med. 1995; 181(5):1911-1915. (Biology). View Reference
  11. Scriba A, Grau V, Steiniger B. Phenotype of rat monocytes during acute kidney allograft rejection: increased expression of NKR-P1 and reduction of CD43. Scand J Immunol. 1998; 47(4):332-342. (Biology). View Reference
  12. Scriba A, Schneider M, Grau V, van der Meide PH, Steiniger B. Rat monocytes up-regulate NKR-P1A and down-modulate CD4 and CD43 during activation in vivo: monocyte subpopulations in normal and IFN-gamma-treated rats. J Leukoc Biol. 1997; 62(6):741-752. (Biology). View Reference
  13. Trinite B, Voisine C, Yagita H, Josien R. A subset of cytolytic dendritic cells in rat. J Immunol. 2000; 165(8):4202-4208. (Biology). View Reference
  14. Webster GA, Bowles MJ, Karim MS, Wood RF, Pockley AG. Activation antigen expression on peripheral blood neutrophils following rat small bowel transplantation. NKR-P1 is a novel antigen preferentially expressed during allograft rejection. Transplantation. 1994; 58(6):707-712. (Biology). View Reference
View All (14) View Less
750314 Rev. 4

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.